Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes
Journal of Diabetes Investigation · 2026
DOI: 10.1111/jdi.70189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Miho Murashima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Inflammation, Diabetes Mellitus, Type 2, Hemoglobins. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction This study aimed to investigate whether the use of sodium‐glucose co‐transporter 2 inhibitors (SGLT2is) is associated with an increase in hemoglobin in the presence of chronic inflammation. Materials and Methods This is a matched‐pair cohort study. Patients with diabetes who visited outpatient clinics from 2019 to 2023 were enrolled. New users and never‐users of SGLT2is were matched by propensity scores, separately for those with C‐reactive protein (CRP) levels lower than and higher than the median time‐averaged CRP. Hemoglobin levels at the last visit for given estimated glomerular filtration rates (eGFR) were estimated using robust regression models with cubic terms of eGFR as covariates. Changes in hemoglobin, CRP, and mean corpuscular volume (MCV) were compared using mixed‐effects models.
Results
Among 1835 never‐users and 690 new users of SGLT2i, 209 and 127 pairs were matched for those with lower and higher time‐averaged CRP, respectively. Hemoglobin levels at the last visit were higher among new SGLT2i users, irrespective of CRP levels ( P for interaction 0.25). During the first 6 months, hemoglobin increased among new SGLT2i users while it decreased among never‐users, and the difference in the trajectories of hemoglobin was more prominent among those with higher time‐averaged CRP ( P for 3‐way interaction 0.02). CRP remained stable irrespective of SGLT2i use and MCV increased among SGLT2i users with higher CRP levels.
Conclusions
SGLT2i use was associated with an increase in hemoglobin levels irrespective of chronic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- Division of Nephrology, Department of Internal Medicine, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Nephrology, Nagoya City University West Medical Center, Nagoya, Japan.
- Department of Nephrology, Nagoya City University East Medical Center, Nagoya, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Nephrology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Maki Hiratsuka, Takayuki Hamano
Zitieren
APA
Murashima, M., Suzuki, K., Kasugai, T., Miyaguchi, Y., Hiratsuka, M., Tomonari, T., Ono, M., Mizuno, M., Tanaka, T., & Hamano, T. (2026). Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70189
Vancouver
Murashima M, Suzuki K, Kasugai T, Miyaguchi Y, Hiratsuka M, Tomonari T, et al. Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70189
BibTeX
@article{Murashima2026,
author = {Murashima, Miho and Suzuki, Kodai and Kasugai, Takahisa and Miyaguchi, Yuki and Hiratsuka, Maki and Tomonari, Tatsuya and Ono, Minamo and Mizuno, Masashi and Tanaka, Tomohiro and Hamano, Takayuki},
title = {Chronic inflammation is not associated with attenuated sodium‐glucose co‐transporter 2 inhibitor‐induced hemoglobin increase in patients with diabetes},
journal = {Journal of Diabetes Investigation},
year = {2026},
doi = {10.1111/jdi.70189}
}
EUVIMED